A
Alex Lopez
Researcher at Regeneron
Publications - 3
Citations - 897
Alex Lopez is an academic researcher from Regeneron. The author has contributed to research in topics: Exome & Biobank. The author has an hindex of 3, co-authored 3 publications receiving 491 citations.
Papers
More filters
Journal ArticleDOI
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Frederick E. Dewey,Viktoria Gusarova,Richard L Dunbar,Colm O'Dushlaine,Claudia Schurmann,Omri Gottesman,Shane McCarthy,Cristopher V. Van Hout,Shannon Bruse,Hayes Dansky,Joseph B. Leader,Michael F. Murray,Marylyn D. Ritchie,H. Lester Kirchner,Lukas Habegger,Alex Lopez,John Penn,An Zhao,Weiping Shao,Neil Stahl,Andrew J. Murphy,Sara Hamon,Aurelie Bouzelmat,Rick Zhang,Brad Shumel,Robert Pordy,Daniel A. Gipe,Gary Herman,Wayne H-H Sheu,I-Te Lee,I-Te Lee,Kae-Woei Liang,Kae-Woei Liang,Xiuqing Guo,Jerome I. Rotter,Yii-Der Ida Chen,William E. Kraus,Svati H. Shah,Scott M. Damrauer,Aeron Small,Daniel J. Rader,Anders Berg Wulff,Børge G. Nordestgaard,Anne Tybjærg-Hansen,Anita M. van den Hoek,Hans M.G. Princen,David H. Ledbetter,David J. Carey,John D. Overton,Jeffrey G. Reid,William J. Sasiela,Poulabi Banerjee,Alan R. Shuldiner,Ingrid B. Borecki,Tanya M. Teslovich,George D. Yancopoulos,Scott Mellis,Jesper Gromada,Aris Baras +58 more
TL;DR: Genetic and therapeutic antagonism of ANGPTL3 in humans and of Angptl3 in mice was associated with decreased levels of all three major lipid fractions and decreased odds of atherosclerotic cardiovascular disease.
Journal ArticleDOI
Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank.
Joseph D. Szustakowski,Suganthi Balasubramanian,Erika Kvikstad,Shareef Khalid,Paola G. Bronson,Ariella Sasson,Emily Wong,Daren Liu,J. Wade Davis,Carolina Haefliger,A. Katrina Loomis,Rajesh Mikkilineni,Hyun Ji Noh,Samir Wadhawan,Xiaodong Bai,Alicia Hawes,Olga Krasheninina,Ricardo Ulloa,Alex Lopez,E. N. Smith,Jeffrey F. Waring,Christopher D. Whelan,Ellen A. Tsai,John D. Overton,William J. Salerno,Howard J. Jacob,Sándor Szalma,Heiko Runz,Gregory Hinkle,Paul Nioi,Slavé Petrovski,Melissa R. Miller,Aris Baras,Lyndon J. Mitnaul,Jeffrey G. Reid +34 more
TL;DR: The UK Biobank Exome Sequencing Consortium (UKB-ESC) as mentioned in this paper is a private-public partnership between the UK Biopartition and eight biopharmaceutical companies that will complete the sequencing of exomes for all ~500,000 UKB participants.
Posted ContentDOI
Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
Joseph D. Szustakowski,Suganthi Balasubramanian,Ariella Sasson,Shareef Khalid,Paola G. Bronson,Erika Kvikstad,Emily Wong,Daren Liu,J. Wade Davis,Carolina Haefliger,A. Katrina Loomis,Rajesh Mikkilineni,Hyun Ji Noh,Samir Wadhawan,Xiaodong Bai,Alicia Hawes,Olga Krasheninina,Ricardo Ulloa,Alex Lopez,E. N. Smith,Jeff Waring,Christopher D. Whelan,Ellen A. Tsai,John D. Overton,William J. Salerno,Howard Jacob,Sándor Szalma,Heiko Runz,Greg Hinkle,Paul Nioi,Slavé Petrovski,Melissa R. Miller,Aris Baras,Lyndon J. Mitnaul,Jeffrey G. Reid +34 more
TL;DR: Early results from the exome sequence data generated by the UKB-ESC for the first ~200,000 UKB subjects are described and the rationale for the use of human genetics in drug discovery as well as lessons learned are described.